LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific (EUFI.PA), the global leader in food testing, announces the acquisition of Gözlem Gýda Kontrol ve Araþtýrma Laboratuvarlarý (“Gözlem”), one of the leading food testing laboratories in Turkey.
Founded in 2002, Gözlem has established itself as one of the main food testing laboratories in the country, and has strong relationships in the national food and beverage industry. The company employs 124 staff, and operates 1 large laboratory in Istanbul, as well as internal laboratories at 13 client sites in Istanbul, Ankara and Izmir regions.
The acquisition of Gözlem provides Eurofins with a strong platform to accelerate the roll-out of its capabilities to serve the thriving food and beverage industry, which at almost 19% of GDP, remains a key trading sector1 in Turkey. In return, Gözlem will be able to leverage Eurofins’ network capabilities and unequalled tests portfolio to accelerate its market share expansion and secure market leadership in the fastest-growing regions of Turkey.
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of Gözlem is another demonstration of our commitment to continuously reinforce our market leadership in the EMEA region. We are looking forward to strengthening Gözlem’s market position by giving it access to the full range of services and capabilities of the Eurofins Group.”
For more information, please visit www.eurofins.com.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 27,000 staff in 310 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.